AGP Executive Report
Last update: 12 hours agoBiotech Manufacturing Deal: AGC Biologics has been picked by Teikoku Seiyaku to develop and manufacture its rhMMP-7 therapy (KTP-001) for lumbar disc herniation, covering cell bank creation, process development and GMP clinical production—starting in Heidelberg before moving to Japan. Markets Mood: Risk appetite lifted as investors priced in a possible Iran-related diplomatic breakthrough, pushing equities higher and oil lower; attention now turns to New Zealand’s central bank decision. EU Policy Tension: A fresh German-led “associate membership” idea for Ukraine is set to dominate EU minister talks in Brussels, with Kyiv rejecting it as a “waiting room” without a seat. Corporate M&A Shockwave: Delivery Hero shares jumped after Uber’s €33-per-share takeover approach, with investors reportedly wanting closer to €40 and regulators likely to scrutinize any deal. Energy/Finance Angle: Germany’s AMANN Group plans factory expansion in Bangladesh, underscoring continued industrial investment links despite global trade friction.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result.
Perspectify News
